anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a remedy for athlete's food wherein vinegar itself is provided with electromotive force, by blending vinegar with newspapers and photographic advertisement papers, stirring them, fitering them. CONSTITUTION:Vinegar is put in a container. Newspapers having magnetism and photographic advertisement papers containing heavy metals and electrically- conductive metals are cut into pieces respectively, put in the container, stirred for more than 8hr at >=98rpm speed, and allowed to stand for 3 days in a state as it is. The solutionis filtered with a cotton cloth, and allowed to stand for >=3 days. The aqueous solution is separated into three layers, and the uppermost layer is used as a remedy for athlete's foot. When a hand or foot affected by athlete's foot is immersed in the solution, the human body itself is earthed, a weak electric current flows, and Trichophyton can be sterilized.
ONCR-177 is an intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1 (herpes simplex virus type 1) that selectively replicates in tumor tissue. Oncorus Inc. is developing ONCR-177 both as monotherapy and in combination with PD-1 blockade for the treatment of advanced solid tumor malignancies. This first-in-human (FIH) Phase 1 dose escalation and expansion study will determine the intratumoral dose of ONCR-177 as a monotherapy and in combination with pembrolizumab, in subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors or with Liver Metastases of Solid Tumors. This protocol will enroll subjects who have at least one lesion that is visible, palpable or detectable and can be injected, and subjects who have liver metastases of solid tumors. Subjects with any cancer types who are eligible for the trial and have such lesions can be considered for enrollment. Additionally, preliminary evidence for clinical and immunologic activity will be sought to guide ongoing studies and development of ONCR-177 in subjects with cancers that are unmet medical needs. Confirmation of safety of ONCR-177 administration in combination with pembrolizumab will also be evaluated in this study, to enable development as part of combination immunotherapy.
Stavudine (d4T), a synthetic thymidine nucleoside analogue, active against the human immunodeficiency virus (HIV). 

Stavudine Capsules are supplied for oral administration in strengths of 15, 20, 30, and 40 mg of stavudine. Each capsule also contains inactive ingredients microcrystalline cellulose, sodium starch glycolate, lactose anhydrous, and magnesium stearate. The hard gelatin shell consists of gelatin, sodium lauryl sulfate, titanium dioxide, and iron oxides.The capsules are printed with Black ink containing black iron oxide E172 dye. 

The chemical name for stavudine is 2',3'-didehydro-3'-deoxythymidine. Stavudine has the following structural formula:

Stavudine is a white to off-white crystalline solid with the molecular formula C10 H12 N2 O4 and a molecular weight of 224.2. The solubility of stavudine at 23° C is approximately 83 mg/mL in water and 30 mg/mL in propylene glycol. The n-octanol/water partition coefficient of stavudine at 23° C is 0.144.
Robust speech communication requires that listeners learn linguistically-relevant representations for stable language regularities, such as the speech sounds (phonemes) that convey meaning. In an increasingly multilingual society, as many as twenty percent of Americans accomplish this across multiple languages. Yet, second language acquisition is especially challenging among adult language learners, for whom learning typically involves explicit classroom instruction. Troublingly, research documents that instruction routinely results in a 'learning plateau' whereby language abilities stagnate or even atrophy despite continued instruction. There is a need to establish effective new approaches to nudge adult language learners off this plateau. This project integrates theoretical and methodological developments in auditory category learning with approaches to classroom-based L2 instruction. Specifically, incidental category learning (in which learners' attention is directed away from to-be-learned categories by an engaging videogame) taps into category learning systems distinct from those engaged in more explicit learning. Moreover, incidental learning of nonspeech sound categories leads to activation of putatively speech-selective cortex associated with speech categorization, suggesting potential representational cross-talk. This guides the central hypothesis of the project: incidental learning of nonspeech perceptual building block categories may provide a 'back door' through which to influence adult L2 learners' speech acquisition and to move them off the classroom learning plateau. An intensive 8-week incidental training study will test the hypothesis (Aim 1). Comparison of incidental nonspeech training with explicit L2 speech training will assess whether this cognitive 'back door' may be more effective in promoting L2 speech perception and production than explicit training with L2 speech and will determine the extent to which each interacts with classroom instruction in the L2 (Aim 2). The results will reveal whether nonspeech, auditory categories sharing common perceptual dimensions with second language categories scaffold L2 acquisition, the degree to which explicit instruction may support or interfere with new auditory categories, whether incidental learning is retained after training, and whether learning gains transfer to support other language-learning tasks. In blending empirical, methodological, and theoretical advances from laboratory studies with explicit classroom learning it will be possible to determine the interplay between incidentally-acquired nonlinguistic perceptual building block categories and an emerging L2. This will advance important theoretical debates about the cross-talk between general auditory representations and speech categories and will provide a novel approach to L2 pedagogy.
Surgical procedures can cause pain and anxiety in patients, affecting their comfort levels. Orthopedic surgeries, in particular, are associated with high pain levels. For example, common orthopedic procedures like total knee and hip replacement can cause patients to experience severe pain on the first-day post-surgery. In modern surgical practices, pain management requires the combined use of both pharmacological and non-pharmacological methods. Additionally, various stressors in the hospital environment-such as the sounds of medical devices and monitors, and crowded hospital rooms-can create extra stress for orthopedic patients, especially those with limited mobility. Another important factor is the interaction among patients in the same environment. The presence of another patient in the same room can affect not only environmental comfort but also, through "emotional contagion," the patient's emotional state. Emotional contagion is defined as the transfer of emotions from one person to another, and this interaction can trigger patients' pain and anxiety levels. Particularly, patients who have undergone similar surgical experiences may share each other's emotions empathetically, thereby increasing pain and anxiety. This study aims to examine the effects of patient interaction in the same room on pain, anxiety, and comfort in orthopedic patients.

The study population will consist of patients who undergo lower and upper extremity surgeries in the orthopedics and traumatology clinic of a state hospital in Turkey. Patients who undergo the same surgical procedure on the same day and stay in the same room postoperatively, or those who are in single rooms, will form the study sample. To obtain reliable results, at least 128 patients will be required, with 64 patients in the group sharing a room and 64 patients in the single-room control group. The goal is to reach this sample size during the planning and implementation phases of the research. Considering a 10% patient dropout rate, 70 patients in the shared room group and 70 patients in the single room group, for a total of 140 patients, will be included in the study. Patients will be grouped according to lower and upper extremity surgeries, and pairs will be formed for placement in the same rooms. Patients discharged within 24 hours will be evaluated during their hospital stay. Additionally, a control group of patients in single rooms will be included to assess the impact of staying in the same room.

Before surgery, the patients' trait anxiety levels will be measured using the State-Trait Anxiety Inventory. After the surgery, once patients are placed in their rooms, pain will be assessed at 1, 4, 8, 12, 16, and 24 hours using the Visual Analog Scale for pain at the surgical site, back, and head/neck. Also, at 1, 8, and 24 hours, their state anxiety and immobilization comfort will be evaluated.
Study participants receive standard therapy (induction and maintenance) for lupus nephritis in addition to receiving either placebo (no active medicine) or belimumab. Induction therapy starts before the first dose of study drug (belimumab or placebo). Maintenance therapy begins after completion of induction therapy and continues for the remainder of the study. Participants receive study drug throughout the entire study, during both induction and maintenance periods. The controlled period of the study is 104 weeks. The random assignment in this study is "1 to 1" which means you have an equal chance of receiving treatment with belimumab or placebo. Participants who successfully complete the 104-week study may enter into a 6-month open-label extension. All participants in the open-label extension receive belimumab.
OBJECTIVE: Transvaginal mesh surgery for pelvic organ prolapse has been widely performed in Japan, but polypropylene mesh has not been used in Japan since the ban on TVM using polypropylene mesh in the United States. Currently, polytetrafluoroethylene mesh ORIHIME® is the only mesh available for TVM in Japan. Although polytetrafluoroethylene is a safe material, its low coefficient of friction and insufficient adhesion to the surrounding tissue make it difficult to maintain the mesh position when it is used in the transvaginal mesh surgery. The aim of this study was to evaluate the feasibility of TVM-A2 using ORIHIME®.
METHODS: One hundred cases of TVM-A2 were included in the study. The patients were randomly assigned to two groups: the ORIHIME® group (Group O) and the PolyformTM group (Group P). With 50 patients in each group, the complications and recurrences up to the fourth year were compared. Surgeries were performed using the TVM-A2 method. Statistical analysis was performed using EZR.
RESULTS: There were no significant differences in baseline parameters between the two groups. We observed no perioperative complications, and saw one case of postoperative abscess formation in Group O, which resolved successfully after incision and drainage. The 4-year recurrence rate was significantly higher in Group O.
CONCLUSION: As the recurrence rate was significantly higher in Group O, we conclude that TVM-A2 using ORIHIME® which is the same procedure as TVM-A2 using polypropylene mesh is not feasible in repairing the pelvic organ prolapse.
The present invention belongs to the field of medicine, and specifically relates to the use of Selonsertib in the preparation of a drug for treating cancers. The Selonsertib is the English name of the compound 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide, and has the chemical formula of C24H24FN7O, and CAS No.: 1448428-04-3. Research results show that Selonsertib can efficiently inhibit the activity of RSK4 kinase, has a remarkable inhibitory effect on the growth of a variety of tumors, and can reduce the drug resistance of tumors to EGFR-TKI targeted drugs when used in combination with EGFR-TKI targeted drugs. The combination of Selonsertib and Anti-PD1 shows a significant inhibitory effect on tumor growth compared with that of Selonsertib alone. A pharmaceutical composition containing Selonsertib has good application prospects in the targeted treatment of a variety of cancers.
OBJECTIVES: Central sensitivity (CS) is defined as an increased responsiveness of nociceptive neurons in the central nervous system to normal or subthreshold inputs. CS has recently been linked to the psychological burden associated with chronic pain, such as fibromyalgia (FM). The primary objective of this study is to investigate the impact of specific psychological constructs on CS in patients with FM. In Study 1, we explore the influence of temperament, personality, childhood trauma, defence mechanisms, and mental pain on CS. In Study 2, our goal is to test the role of the best predictors of CS in influencing quality of life (QoL) and FM functioning through a path analysis model.
METHODS: A total of 510 women with FM participated online, completing a self-administered protocol. Data collection took place between April and June of 2023.
RESULTS: In Study 1, higher levels of low sensory threshold (β=0.210), traumatic experiences of physical threat (β=0.141), neurotic defences (β=0.124), and mental pain (β=0.241) emerged as the strongest predictors of increased CS. In Study 2, the presented model demonstrated a satisfactory fit (chi2=27.200; df=10; p=0.002; GFI=0.984; NFI=0.949; CFI=0.967; RMSEA=0.061 [95% CI 0.034-0.090]) with large and medium effect sizes on physical (-0.576) and psychological (-0.190) QoL.
CONCLUSIONS: The study underscores the pivotal role of psychological dimensions in influencing CS levels and their relationships with QoL in patients with FM.
About 200 patients with NSCLC planned to start an innovative therapy (e.g. immunotherapy, targeted therapy) will be included.
PURPOSE: A transdermal delivery system of a skin physiologically active molecule which is fused with an intracellular molecule transduction peptide is provided to ensure excellent skin permeability, to effectively deliver a beneficial compound to a skin cell, and to be used as an ingredient of a functional cosmetic material by formulating in various types. CONSTITUTION: A composition for transdermal delivery contains a skin physiologically active molecule which is conjugated to a molecular transduction peptide. The composition has an amino acid sequence selected from the group consisting of sequence numbers 15-35. The composition is a makeup composition. A transdermal delivery system transfers an intracellular molecular transduction peptide by conjugation with the skin physiologically active molecule. A method for delivering the skin physiologically active molecule to the skin cell comprises a step of conjugating the intracellular molecular transduction peptide with the skin physiologically active molecule and delivering the intracellular molecular transduction peptide.
In Part 1, single ascending intravenous (IV) doses of JNJ-63733657 or placebo will be administered to sequential cohorts (Cohorts 1 to 5) of healthy subjects on Day 1. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. Here, SAD indicates single ascending dose.
Afyonkarahisar University of Health Sciences Non-Invasive Clinical Research Ethics Committee evaluated the study with the 2011-KAEK-2 ethics committee code. The study was planned to be carried out in Afyonkarahisar State Hospital Occupational Therapy Unit. It was planned to include 30 children between the ages of 7 and 12 who were diagnosed with ADHD according to the DSM-5 criteria by a child psychiatrist. Children will be randomly divided into two groups: 15 in the intervention group and 15 in the control group. At the beginning of the study, the purpose of the study will be explained to the family and the child and informed consent forms will be signed. Standard tests will be applied after the sociodemographic information of the child and his family is obtained. With the CO-OP approach, the intervention group will receive two sessions of therapy per week, each for approximately one hour, for a total of 6 weeks and 12 sessions. After 6 weeks, standard assessments will be repeated. The control group will receive the same standardized assessments at baseline and 6 weeks later with no further intervention.
Patients with metastatic pancreatic cancer receiving will be asked to fill in an EORTC QLQ-C30 questionnaire and additional questionnaires on worries about quality of life impairments and physical constitiution every 8 weeks, over the entire course of treatment, starting with neo-/adjuvant or 1st line therapy follow. There is no restriction on type of therapy. No further intervention.
A sorter of medical findings for assessment by a medical coder is provided. In some embodiments, the sorter receives information about a user (coder), including identification, a role, and historical activity. The sorter determines whether to run in exploration or exploitation modes. Exploration is used to explore the scope of the findings and also identify variables that impact a finding. Exploitation is designed to maximize a goal (such as throughput or profitability). Lastly a finding is selected and provided to the user. The selection is based upon computing internal parameters when in exploration, or based upon optimizing for criteria when in exploitation. The sorter may also determine competency for the user, and cut them off from performing additional coding if they are found incompetent.
Whereas 16p11.2 BP4-5 copy-number variants (CNVs) represent one of the most pleiotropic etiologies of genomic syndromes in both clinical and population cohorts, the mechanisms leading to such pleiotropy remain understudied. Identifying 73 deletion and 89 duplication carrier individuals among unrelated White British UK Biobank participants, we performed a phenome-wide association study (PheWAS) between the region's copy number and 117 complex traits and diseases, mimicking four dosage models. Forty-six phenotypes (39%) were affected by 16p11.2 BP4-5 CNVs, with the deletion-only, mirror, U-shape, and duplication-only models being the best fit for 30, 10, 4, and 2 phenotypes, respectively, aligning with the stronger deleteriousness of the deletion. Upon individually adjusting CNV effects for either body mass index (BMI), height, or educational attainment (EA), we found that sixteen testable deletion-driven associations-primarily with cardiovascular and metabolic traits-were BMI dependent, with EA playing a more subtle role and no association depending on height. Bidirectional Mendelian randomization supported that 13 out of these 16 associations were secondary consequences of the CNV's impact on BMI. For the 23 traits that remained significantly associated upon individual adjustment for mediators, matched-control analyses found that 10 phenotypes, including musculoskeletal traits, liver enzymes, fluid intelligence, platelet count, and pneumonia and acute kidney injury risk, remained associated under strict Bonferroni correction, with 10 additional nominally significant associations. These results paint a complex picture of 16p11.2 BP4-5's pleiotropic pattern that involves direct effects on multiple physiological systems and indirect co-morbidities consequential to the CNV's impact on BMI and EA, acting through trait-specific dosage mechanisms.
We aimed to assess the impact of hospital characteristics on the outcomes of detected possible brain-dead donors, in our organ procurement network in Iran. Data was collected through twice-daily calls with 57 hospitals' intensive care units and emergency departments over 1 year. The donation team got involved when there was suspicion of brain death before the hospital officially declared it. The data was categorized by hospital size, presence of neurosurgery/trauma departments, ownership, and referral site. Out of 813 possible donors, 315 were declared brain dead, and 203 were eligible for donation. After conducting family interviews (consent rate: 62.2%), 102 eligible donors became actual donors (conversion rate: 50.2%). While hospital ownership and the presence of trauma/neurosurgery care did not affect donation, early referral from the emergency department had a positive effect. Therefore, we strongly recommend prioritizing possible donor identification in emergency rooms and involving the organ donation team as early as possible. The use of twice-daily calls for donor identification likely contributed to the consistency in donation rates across hospitals, as this approach involves the donation team earlier and mitigates the impact of hospital characteristics. Early detection of possible donors from the emergency department is crucial in improving donation rates.
Pancreatitis has been observed in patients receiving lopinavir and ritonavir therapy, including those who developed marked triglyceride elevations. In some cases, fatalities have been observed. Although a causal relationship to lopinavir and ritonavir has not been established, marked triglyceride elevations are a risk factor for development of pancreatitis [ see Warnings and Precautions (5.9)] . Patients with advanced HIV-1 disease may be at increased risk of elevated triglycerides and pancreatitis, and patients with a history of pancreatitis may be at increased risk for recurrence during lopinavir and ritonavir therapy. 

  


Pancreatitis should be considered if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of pancreatitis occur. Patients who exhibit these signs or symptoms should be evaluated and lopinavir and ritonavir and/or other antiretroviral therapy should be suspended as clinically appropriate.
Piroxicam capsules, USP are a nonsteroidal anti-inflammatory drug, available as white opaque/red opaque 10 mg capsules and red opaque 20 mg capsules for oral administration. The chemical name is 4-hydroxyl-2-methyl-N-2- pyridinyl-2H-1,2,-benzothiazine-3-carboxamide 1,1-dioxide. The molecular weight is 331.35. Its molecular formula is C15H13N3O4S, and it has the following chemical structure. 

Piroxicam occurs as a white crystalline solid, sparingly soluble in water, dilute acid, and most organic solvents. It is slightly soluble in alcohol and in aqueous solutions. It exhibits a weakly acidic 4-hydroxy proton (pKa 5.1) and a weakly basic pyridyl nitrogen (pKa 1.8). 

The inactive ingredients in piroxicam capsules, USP include: corn starch, FD & C Blue 1, FD & C Red 40, gelatin, lactose monohydrate, magnesium stearate, sodium lauryl sulfate and titanium dioxide.
This application relates to a microdevice for delivering drugs to a target location. The microdevice comprises a plurality of nanocapsules assembled together, each having an outer hydrophobic shell and an inner liquid core contained within the shell. At least one drug is dissolved within the inner liquid core. The liquid core comprises a mixture of solvents including at least one solvent for maintaining the hydrophilicity of the inner core (and hence the phase difference between the polymeric shell and the liquid core) and at least one second solvent for enhancing the solubility and bioavailability of the drug. For example, the second solvent may be selected to enable a hydrophobic drug to dissolve within the hydrophilic inner core environment. The inner core may also include a small amount of water-soluble polymer. The application also relates to a method of making the microdevices by formulating a homogenous emulsified solution containing the drug and forming the nanocapsules from the emulsified solution, such as by an atomization process.